top of page
%20(11_087%20x%207%20in).jpg)
NEW BOOK
LATEST NEWS
Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance Gene Editing for Heart Disease
Eli Lilly has announced it will acquire Verve Therapeutics for up to $1.3 billion . The deal will help Lilly develop gene-editing...
Jul 20
Capricor's Shares Drop After FDA Rejects Deramiocel Cell Therapy for Heart Disease in DMD
Capricor Therapeutics faced a significant setback on July 11, 2025, when the FDA rejected its cell therapy, Deramiocel , for treating...
Jul 16
FDA Rejects Ultragenyx's Gene Therapy for Rare Disease - Sanfilippo Syndrome
The FDA has declined to approve Ultragenyx Pharmaceutical's gene therapy, UX111, for treating Sanfilippo syndrome type A, a rare genetic...
Jul 16
GENE TECH TIMES
The Future Has Arrived
Lenmeldy: The First FDA-Approved Gene Therapy for Metachromatic Leukodystrophy in Children
Lenmeldy , a groundbreaking gene therapy developed by Orchard Therapeutics , has recently received FDA approval , making it the first and...
Apr 15, 2024
bottom of page